Quality Medical Care for People Who Use Drugs

Brad Finegood, MA, LMHC; Judith Tsui, MD, MPH; Richard Waters, MD; Shireesha Dhanireddy, MD

Presented by Public Health-Seattle & King County

January 14, 2021
Housekeeping

- For audio:
  - Select “Join with Computer Audio,” OR
  - Select “Join by Phone,” then dial the phone number and meeting ID when prompted.
- You will be muted automatically upon entry. Please keep your phone line muted for the duration of the webinar.
- Webinar is being recorded and will be archived for future viewing at [www.pcssNOW.org](http://www.pcssNOW.org) within 2 weeks.
- Submit questions in the Q&A box at the bottom of your screen.
Target Audience

- The overarching goal of PCSS is to train healthcare professionals in evidence-based practices for the prevention and treatment of opioid use disorders, particularly in prescribing medications, as well for the prevention and treatment of substance use disorders.
Disclosures

• Mr. Finegood, Dr. Dhanireddy and Dr. Waters have no financial relationships or conflicts of interest.

• Dr. Tsui’s disclosures:
  ▪ Site PI for a Patient Centered Outcomes Research Institute (PCORI) funded study of models of HCV for which medications are provided by Gilead.
  ▪ PI of NIH/NIDA funded studies in partnership with mHealth technology company (emocha) for video-directly observed therapy of methadone and buprenorphine.

The content of this activity may include discussion of off label or investigative drug uses. The faculty is aware that is their responsibility to disclose this information.
INTRODUCTION

Brad Finegood,
Strategic Advisor,
Public Health—Seattle & King County
As we begin our talk, we respectfully acknowledge that our event today (where we are) is taking place on occupied Coast Salish land on the homelands of the Duwamish people.

We pay respect to Coast Salish Elders past and present and extend that respect to their descendants and to all Indigenous people.

To acknowledge this land is to recognize its longer history and our place in that history.
Provider Introduction

- Advancing opportunities for recovery from substance use disorders by providing compassionate care and partnering with harm reduction services providers.
  - Dr. Judith Tsui
  - Dr. Richard Waters
  - Dr. Shireesha Dhanireddy
Harm reduction is quality medical care.
Educational Objectives

- At the conclusion of this activity participants should be able to:
  - Recognize the importance of harm reduction strategies in the provision of quality medical care.
  - Identify partnership opportunities for physicians and harm reduction providers to provide compassionate care to people who use drugs.
  - Take a substance use history and strategize with patients to use more safely.
  - Recognize how stigma contributes to negative outcomes.
  - Address co-morbidities and social factors.
  - Design patient-centered approaches to care delivery models.
  - Discuss management strategies for non-opioid substances in OUD treatment.
  - Recognize the value in caring for patients who repeatedly start & stop buprenorphine.
  - Approach probable or confirmed medication diversion in a health-centered manner.
  - Understand epidemiology of HIV and STIs in people who inject drugs.
DISCUSSING SUBSTANCE USE AND ADDRESSING COMORBIDITIES

Dr. Judith Tsui
Physician, University of Washington Medicine
What is Harm Reduction?

• “… a pragmatic approach to reduce the harmful consequences of alcohol and drug use… The primary goal of most harm-reduction approaches is to meet individuals where they are at…” (Marlatt GA and Witkiewitz K, 2010)

• It is an approach that is rooted in both pragmatism and compassion (Collins SE and Clifasefi S, 2017)
What is Harm Reduction?

• Focus is on sustaining health and reducing harms associated with use
• Cessation of use/abstinence is not an expectation
  ▪ Reduction of use may or may not be goal
• Priorities/goals are set by patient
Harm Reduction is Patient-Centered Care

• “Patient-centered care is considered to be care that is relationship-based, and makes the patient feel known, respected, involved, engaged and knowledgeable.” (Schottenfeld 2016)

• Providers allow individual values and preferences to shape care.

• Patient-centered care has been shown to be associated with improved health status, treatment adherence and greater efficiency of care. (Stewart M 2000; Zolnierek 2009)
Primary care is full of examples of respecting preferences/reducing harm

- Consider the following scenarios where providers must “meet patients where they are”:
  - Patient is due for repeat colonoscopy for polyps. Says “I’m never doing that again!”
  - Diabetic patient has uncontrolled blood glucose, specialist recommends insulin, but patient refuses, stating “I hate needles”.
  - Patient who had recent cardiac bypass surgery who continues to smoke cigarettes
- Quality, patient-centered care = harm reduction
#1: Use person-first language and a collaborative interview style
Provider stigma impacts patient health

- Stigma is a major reason why patients don’t seek care, and they don’t remain engaged in care, for substance use disorder (Tsai, 2019)
- Language matters: Clinicians have more negative responses to patients described as “substance abusers” v. “person with a substance use disorder” (Kelly and Westerhoff, 2010)
Use non-stigmatizing, person-first language

**SAY**
- Substance use disorder
- Person with substance use disorder
- Positive, negative urine test
- Recurrence of use
- Pharmacotherapy, medication for use disorder, agonist therapy

**AVOID**
- Drug abuse/abuse
- Addict, junkie
- Dirty, clean urine
- Clean, sober
- Relapse/fall off the wagon
- Substitution therapy

Take a good substance use history

• Ask permission to ask sensitive information
• Express gratitude and listen when they share their stories
• Let patients know that your questions are standard, asked the same way for all patients
• Reassure patient that care is not contingent on their responses, your intent is to provide them with help (if desired)
• Frame questions neutrally in a way that doesn’t assume non-use
Asking About Substance Use

- Study of 162 patients with recent use of alcohol, cocaine, heroin, multiple substances found providers failed to ask in 50% of encounters (Callon JGIM 2016)
- When providers asked, it mattered how they asked whether a patient would disclose use
  - Open-ended and normalizing ("Tell me what’s happening with drugs") → 100% disclosure
  - Closed-ended and leaning toward non-use ("And you haven’t been using any drugs?") → 22-58% disclosure

#2 Strategize how to use safely
Safer drug use strategies

- Carry naloxone
- Avoid using alone, use with people you trust
- Avoid mixing drugs
  - Drugs used together may have greater risk (e.g., stimulants + alcohol, benzos + opioids, etc.)
- Be wary of fentanyl contamination
  - Use fentanyl test strips
  - Use a test dose
- Choose safest mode possible
  - Oral>snort>smoke>inject IV>muscle
Safer injection drug use strategies

• Practice good vein care
  ▪ Rotate injection sites
  ▪ Avoid injecting in neck and groin
  ▪ Clean skin prior to injection
• Avoid sharing any injecting equipment
  ▪ Includes cookers, cottons and rinses
  ▪ Also, don’t reuse your own equipment
• Avoid using drugs in settings that can lead to risky sex
• Consider Pre-Exposure Prophylaxis (PrEP) for HIV

#3 Understand patient’s priorities for care, address co-morbidities like HCV
Addressing co-morbidities and social factors

• Important to address patient’s key concern
  ▪ If not addressed, patient may never return
• Medical issues may not be the priority
  ▪ Housing, food, transportation, legal issues may take precedence
• Substance use should not be a barrier to address other medical issues: treating co-morbidities can improve substance use
  ▪ Example: treating/curing HCV can be transformative experience that leads to engagement in other domains
Psychological and Behavioral Transformation with HCV Treatment

• “Everything changed. I stopped drug use. I stopped everything because I said if I beat the Hep C, I could beat that too.”
• “With this hepatitis and being clean, when I started [HCV treatment], I guess I started being responsible.”
• “I like to think of it as the Hep C treatment turned me around…”

Batchelder AW et al. 2015
Conclusions

• Harm reduction is good primary care
• Use person-first language and a collaborative interview style when discussing substance use
• Introduce strategies for safe use, allow patient to set goals
• Discuss care priorities, offer treatment for common co-morbidities like HCV
PRIMARY CARE DELIVERY MODELS FOR PWUD

Dr. Richard Waters
Site Medical Director, Housing & Street Outreach
NeighborCare Health
100% access?

Traditional primary care model:
• Brick-&-mortar clinic
• Predominantly schedule-based
• 15-20-minute visits, high-throughput
• Limitations in addressing SDoH
• Medical milieu
• Works for many, but not all…

Community-embedded model:
• Embedded within other community services; where people already are at
• Designed for walk-ins
• Longer visits possible
• Lower volumes often
• Co-located services to address SDoH
• Less likely to evoke prior medical-system traumas
The “why” for newer paradigms of primary care

Status quo isn’t working

“Every system is perfectly designed to get the results it gets”
- W. Edwards Deming
Community-embedded models in Seattle

High-value or full primary care services, with OUD focus, embedded within:

- A criminal-legal system diversion program drop-in center for PWUD
- Shelters
- Permanent supportive housing buildings
- A drop-in center for PWUD or are living homeless
- Adjacent to a thrift store
- Syringe-needle exchanges
OUD treatment & primary care: “Meds first”, more later

Medication First philosophy of OUD treatment = pragmatic, outcomes-oriented, patient-centered (Winograd, Am J Drug Alcohol Abuse 2019)

More primary care often follows:

- Infectious disease testing
- Renal function testing
- HCV treatment
- Pre-exposure prophylaxis for HIV
- Contraception management
- Wound care
- Mental health care
Creating quality care for PWUD

• Community-embedded care if possible

• Regardless of location, focus on:
  ▪ **Structural** adaptations in care delivery
  ▪ **Cultural** adaptations in care delivery
Structural adaptations

How you design workflow & your team

• Easily **accessible** location
• Minimal “**waste**” in value stream of care, from the patient perspective
• Walk-ins / **same-day** buprenorphine starts
• **Microdosing** inductions when needed
• **Flexibility** with follow up
• RN care managers **protocols for refills**
• Coordination with **social services**
• **Peer** supports
• On-site **dispensing**
Minimize “waste” in value stream of care, from the patient perspective

E.g.: If the patient’s only goal is starting buprenorphine for OUD:

- Confirm OUD diagnosis
- Assess for current use of naltrexone, methadone, buprenorphine; PMP check
- Assess for pregnancy *
- Screen, by history, for severe liver dysfunction
- Medication interactions?
- Buprenorphine education (starting, taking, keeping safe, follow up)

Ideal but not necessary at 1st visit: lengthy intake, detailed substance use history, mental health history, vital signs, urine drug screen at times, labs, medication “agreements”
Structural adaptions: Starting buprenorphine

• Bupe can be prescribed in encampments, shelters, mobile vans, etc.

• Default to “wherever you are”-based bupe starts, not office-based

• Discuss “microdosing” starting approach as an option

• Prescribe opioid withdrawal treatment medications

• Partner with case managers on hotel options or short-term medical facilities (e.g., detox) for patients living homeless who struggle with starting process
Structural adaptions: Policies around non-opioid use

- Mortality risk reduction with agonist therapy for OUD treatment
- Observational studies = mortality benefit **persistence** with polysubstance use
- Mortality risk reduction of OAT may be **relatively greater** when concurrent alcohol & benzo use exist
- Non-opioid substance use may hinder OUD treatment retention

= Ok to start & continue bupe for OUD with concurrent benzo, alcohol, stimulant or other drug use

= Offer treatments & supports for other use disorders

Structural adaptations: Policies around restarting bupe

- 37 year old with OUD, stimulant use disorders & unstable housing repeatedly started & stopped bupe, at least 10 times over 1.5 years.

- Prescription lengths were 2-7 days

- Other treatment options discussed. She declined (methadone, bupe daily dosing, therapeutic residential communities)

- Then she stabilized on bupe. **Hope** for reuniting with family was key. Her SUDs have been in remission for nearly 3 years, now working full time, housed, with family.
Structural adaptations: Policies around restarting bupe

Days with buprenorphine prescription, based on PDMP data

<table>
<thead>
<tr>
<th>Pt</th>
<th>Bupe Coverage months 0-3</th>
<th>Pt 1</th>
<th>Pt 2</th>
<th>Pt 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pt 1</td>
<td>43%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pt 2</td>
<td>52%</td>
<td>40%</td>
<td>30%</td>
<td>88%</td>
</tr>
<tr>
<td>Pt 3</td>
<td>44%</td>
<td>78%</td>
<td>89%</td>
<td></td>
</tr>
<tr>
<td>Pt 4</td>
<td>26%</td>
<td>63%</td>
<td>100%</td>
<td></td>
</tr>
</tbody>
</table>

Unpublished data
Structural adaptions: Policies around restarting bupe

Hood, et al. Subst Abuse 2020; 41:356
Structural adaptations: Policies around restarting bupe

- Milder OUD, more privilege (e.g., social supports, housing status, financial status), lack of legal issues, lack of other SUDs = greater likelihood of quick stabilization on bupe

- If we limit opportunities to re-engage in care, we apply a selective pressure that benefits the (relatively) more privileged, harms the more vulnerable

- Re-engagements = opportunities for other health care
Cultural adaptations

Maximize psychological safety for our patients

“It’s OK to use heroin, let’s minimize the harms”

“Ok, let’s talk about how you can use heroin and stay on bupe”

“Welcome back!” (for 6th re-start)

Creating welcoming spaces for BIPOC, immigrants, LGBTQI+, non-English speakers

Assessing racism & colonialism embedded with our health structures

Addressing urine tampering while keeping patients engaged
30 year old returned for bupe care.

- POC urine tox immunoassay = bupe positive
- Confirmation = Bupe >1500 ng/mL, norbupe 106 ng/mL
- She disclosed dipping bupe into urine, diverting half her supply to her partner, taking the remaining bupe.

Goal is to minimize under-treatment while minimizing diversion
Diversion

- Most diverted buprenorphine gets used for treating opioid withdrawals and treating OUD

- Psychological safety = increased likelihood of an honest picture of use of bupe

- Periodic norbuprenorphine confirmations can add clinical value

- Occasional monitored dosing or pill/film counts can be helpful at times if concerns arise

Cicero, Drug Alcohol Dependence 2018; 193;117.
Holt, Drug Alcohol Dependence 2018; 186:171
EXCHANGE SEX, HIV, STIS & THE OPIOID EPIDEMIC

Dr. Shireesha Dhanireddy
Physician, University of Washington Medicine
Medical Director of UW’s Madison Clinic, Infectious Diseases Clinic, & SHE Clinic
Patient Story

- 34 year old woman presents to Aurora Commons (community day space)
- She is living homeless, injects methamphetamine and heroin daily
- Reports having exchanged sex with multiple daily partners (oral and vaginal sex)
- Has new boyfriend x 2 months
- Significant mental health issues with h/o psych hospitalization
- She is concerned about her health – has an abscess on her face but also expresses desire to quit using heroin
Patient Story

- She notes she was tested for HIV 2 months prior while in jail and was negative
- She agrees to STI/HIV testing
- **Rapid test for HIV is positive**
## Risk Factors for HIV

### Estimated Per-Act Probability of Acquiring HIV from an Infected Source, by Exposure Act*

<table>
<thead>
<tr>
<th>Type of Exposure</th>
<th>Risk per 10,000 Exposures</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Parenteral</strong></td>
<td></td>
</tr>
<tr>
<td>Blood Transfusion</td>
<td>9,250</td>
</tr>
<tr>
<td>Needle-Sharing During Injection Drug Use</td>
<td>63</td>
</tr>
<tr>
<td>Percutaneous (Needle-Stick)</td>
<td>23</td>
</tr>
<tr>
<td><strong>Sexual</strong></td>
<td></td>
</tr>
<tr>
<td>Receptive Anal Intercourse</td>
<td>138</td>
</tr>
<tr>
<td>Insertive Anal Intercourse</td>
<td>11</td>
</tr>
<tr>
<td>Receptive Penile-Vaginal Intercourse</td>
<td>8</td>
</tr>
<tr>
<td>Insertive Penile-Vaginal Intercourse</td>
<td>4</td>
</tr>
<tr>
<td>Receptive Oral Intercourse</td>
<td>Low</td>
</tr>
<tr>
<td>Insertive Oral Intercourse</td>
<td>Low</td>
</tr>
</tbody>
</table>
Outbreak of HIV Infection in Southeast Indiana
Syringe-Sharing Network of Persons with Newly Diagnoses HIV Infection in Indiana Outbreak
County Vulnerability to HIV & HCV and Syringe-Exchange Status

US Counties’ Vulnerability to HIV and HCV Outbreaks and Their Syringe-Exchange Program (SEP) Status
Lessons Learned from Indiana

- Need for more rapid response to HIV
- Need for syringe exchange services
- Expanded use of buprenorphine and other opiate agonist therapy
HIV Diagnoses, King County PWID, 2009-18
Low Viral Suppression among PWID?

**HIV Viral Suppression, 2017**
- Non-MSM PWID: 80%
- MSM PWID: 79%
- MSM: 87%

**Mean Days to HIV Viral Suppression, 2013-2016**
- Non-MSM PWID: 262 days
- MSM PWID: 122 days
- MSM: 118 days

Slide courtesy of Sara Glick, PhD, MPH
Increasing Methamphetamine Use?

Drugs Injected by PWID in the Past 3 Months, SSP Surveys

Slide courtesy of Sara Glick, PhD, MPH
Ref: King County HIV Epidemiology Report, https://tinyurl.com/KCHIVReport
Increasing Methamphetamine Use?

Any Recent Meth Use, MSM PWID

Any Recent Meth Use, Non-MSM PWID

Slide courtesy of Sara Glick, PhD, MPH
Ref: Glick et al, Drug Alcohol Depend 2017
Evidence of Equipment Sharing


![Bar chart showing proportions of PWID who report injecting meth and sharing injection equipment for MSM and Non-MSM individuals.](chart.png)

Last Sharing
- **Women**
- **Other Men**
- **MSM**

Slide courtesy of Sara Glick, PhD, MPH
Ref: Glick et al, Drug Alcohol Depend 2017
Exchange Sex & HIV

HIV prevalence among women who exchange sex for money or drugs (2016), among high risk heterosexual women who do not exchange sex (2013), and among women in the general population (2015)—Chicago, Detroit, Houston, and Seattle.
Women in Need

- Homelessness
- Exchange sex
- Lack of services
- Stigma

Licton Springs Tiny House Village (photo Seattle Times)
Exchange Sex and HIV

- Overlap of injection drug use and exchange sex increases risk of STIs and HIV
- Increasing number of women engaging in transactional sex in the Seattle area
- Impact of backpages shutdown – higher risk sex
Qualitative interviews of exchange sex workers on North Aurora found the following:

- All surveyed were opiate dependent
- Nearly all did not have medical home/PCP
- Prior interactions with healthcare system were felt to be judgmental and stigmatizing

Data from Laura Hamman, DNP, 2014
Women of North Aurora

• Medical needs assessment performed in 2017
  ▪ Most of the women surveyed wanted full primary care
    – Contraception
    – Vaccines
    – Cancer screening
    – Mental health care
    – Buprenorphine-naloxone
    – STI testing/treatment
    – HIV testing
    – HCV testing and treatment
  ▪ Most had not heard of PrEP
S.H.E. Clinic
SHE Clinic Model

- Began 7/2018
- Walk-in
- Partnership with PSCC, AC, WA DOH, PHPDA (Health Equity Fund)
- Primary care clinic for female-identifying persons on North Aurora Avenue
- MD, RN, full time medical case manager
Evaluation of the first 50 patients

• High STI risk yet none had been tested within 3 months of initial SHE clinic visit
• 29% of women reported condom use
• 50% of women tested were positive for trichomonas
• None reported planning for pregnancy, but 4 with new dx of pregnancy (now up to > 20)
• 42/50 tested for HIV
  ▪ 17 of the HIV negative women initiated PrEP at first visit
• 12 HIV positive women have accessed SHE clinic services but only 3 are in consistent care and on treatment
<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Percent Asked About Characteristic or Tested (n)</th>
<th>% Positive (n)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Average age (IQR)</td>
<td>37 (34, 40)</td>
<td></td>
</tr>
<tr>
<td>Racial identity</td>
<td>98.0 (49)</td>
<td></td>
</tr>
<tr>
<td>White</td>
<td></td>
<td>69.4 (34)</td>
</tr>
<tr>
<td>Black</td>
<td></td>
<td>22.5 (11)</td>
</tr>
<tr>
<td>Native American/Alaskan</td>
<td></td>
<td>2.0 (1)</td>
</tr>
<tr>
<td>Asian</td>
<td></td>
<td>0</td>
</tr>
<tr>
<td>Other</td>
<td></td>
<td>6.1 (3)</td>
</tr>
<tr>
<td>Unstable housing</td>
<td>94.0 (47)</td>
<td>95.7 (45)</td>
</tr>
<tr>
<td>Injection drug use</td>
<td>90.0 (45)</td>
<td>80.0 (36)</td>
</tr>
<tr>
<td>Transactional sex</td>
<td>90.0 (45)</td>
<td>68.9 (31)</td>
</tr>
<tr>
<td>Pregnancy</td>
<td>78.0 (39)</td>
<td>10.3 (4)</td>
</tr>
<tr>
<td>Trichomoniasis</td>
<td>46.0 (23)</td>
<td>47.8 (11)</td>
</tr>
<tr>
<td>Chlamydia</td>
<td>56.0 (28)</td>
<td>17.9 (5)</td>
</tr>
<tr>
<td>Gonorrhea</td>
<td>54.0 (27)</td>
<td>18.5 (5)</td>
</tr>
<tr>
<td>Syphilis</td>
<td>26.0 (13)</td>
<td>0</td>
</tr>
<tr>
<td>HIV</td>
<td>84.0 (42)</td>
<td>8.5 (4)</td>
</tr>
<tr>
<td>Hepatitis C</td>
<td>76.0 (38)</td>
<td>39.5 (15)</td>
</tr>
</tbody>
</table>
SHE Clinic Implementation: Reduction in ED Visits

Visits per woman by complaint and patient group in the 6 months before and after first SHE clinic visit or reference date

- Primary care
  - Non SHE clients before
  - Non SHE clients after
  - Early SHE clients before
  - Early SHE clients after

- Mental health care
  - Non SHE clients before
  - Non SHE clients after
  - Early SHE clients before
  - Early SHE clients after

- Emergent care
  - Non SHE clients before
  - Non SHE clients after
  - Early SHE clients before
  - Early SHE clients after
Now 20 months since her diagnosis
She obtained housing 6 months ago
Still using meth and heroin daily, but smoking not injecting (and intermittently on buprenorphine/naloxone)
But, engaged in SHE Clinic and last HIV RNA is undetectable!
Conclusions

• Women living unhoused and exchanging sex are at high risk for HIV and STIs and have frequent contact with ED providers

• In conjunction with a trusted safe space, a co-located clinic model can provide non-judgmental low barrier HIV, STI, and primary care and lead to decreased ED visits
Next Steps

- Expansion of SHE
- Continue to offer low barrier buprenorphine and optimize delivery
- Partnership with Hepatitis Education Project to assist with HCV treatment adherence support
- STI control – point-of-care testing with expedited partner therapy
- Explore fertility desire – need for in depth qualitative exploration of concepts of motherhood and resistance to LARC
Acknowledgements

UW / HMC / NWH
- Monica Brown, RN
- Maggie Green, MD
- Sherice Arnold, MSW
- Christine McKay, MSW
- Jennifer Magnani, MSW
- Erica Peterson, RN
- Jenell Stewart, MD, MPH
- Kate Stadeli, MD
- Kristjana Asbjornsdottir

Aurora Commons
- Lisa Etter-Carlson
- Elizabeth Dahl
- Kim Muir
- Christina Smith
- Giana Davidson, MD

DOH
- Beth Crutzinger-Perry

Lahai
- Candy McDonald
- Stephanie Chamberlain

PHSKC
- Matt Golden, MD, MPH
- Julie Dombrowski, MD, MPH
- Sara Glick, PhD, MPH

PHPDA
- Jeff Natter

THANK YOU to all the women of North Aurora
Questions?

- Brad Finegood, MA, LMHC, Strategic Advisor, Public Health – Seattle & King County: Brad.Finegood@kingcounty.gov
- Judith Tsui, MD, MPH, Physician, UW Medicine: Tsuij@uw.edu
- Shireesha Dhanireddy, MD, Physician, UW Medicine: Sdhanir@uw.edu
- Richard Waters, MD, Physician, NeighborCare Health: Richardw@neighborcare.org
References

- Cicero, Drug Alcohol Dependence 2018; 193;117
- Doernberg, et al, Substance Abuse; 2019;40:148
- Glick et al, Drug Alcohol Depend 2017
- Hood, et al. Subst Abuse 2020; 41:356
- King County HIV Epidemiology Report, https://tinyurl.com/KCHIVReport
- Knudsen, et al. Drug Alcohol Depend, 2019; 204:107490
- Laura Hamman, DNP, 2014
- Nerlander L et al. JAIDS 2020
- Payne, et al. Drug Alcohol Depend, 2019; 200:71
- Schottenfeld L, Petersen D, Peikes D, Ricciardi R, Burak H, McNellis R, Genevro J. Creating Patient-Centered Team-Based Primary Care. AHRQ Pub. No. 16-0002-EF.
- Stewart J et al. Sex Transm Dis 2020
- Winograd, et al. NEJM, 2018; 379:1
- Zolnierek KB, Dimaatteo MR. Physician communication and patient adherence to treatment: a meta-analysis.
PCSS Mentoring Program

- PCSS Mentor Program is designed to offer general information to clinicians about evidence-based clinical practices in prescribing medications for opioid use disorder.

- PCSS Mentors are a national network of providers with expertise in addictions, pain, evidence-based treatment including medications for addiction treatment.
  
  - 3-tiered approach allows every mentor/mentee relationship to be unique and catered to the specific needs of the mentee.
  
  - No cost.

For more information visit: https://pcssNOW.org/mentoring/
PCSS Discussion Forum

Have a clinical question?

Ask a Colleague
A simple and direct way to receive an answer related to medication-assisted treatment. Designed to provide a prompt response to simple practice-related questions.

http://pcss.invisionzone.com/register
**PCSS** is a collaborative effort led by the American Academy of Addiction Psychiatry (AAAP) in partnership with:

<table>
<thead>
<tr>
<th>Addiction Technology Transfer Center</th>
<th>American Society of Addiction Medicine</th>
</tr>
</thead>
<tbody>
<tr>
<td>American Academy of Family Physicians</td>
<td>American Society for Pain Management Nursing</td>
</tr>
<tr>
<td>American Academy of Pain Medicine</td>
<td>Association for Multidisciplinary Education and Research in Substance use and Addiction</td>
</tr>
<tr>
<td>American Academy of Pediatrics</td>
<td>Council on Social Work Education</td>
</tr>
<tr>
<td>American Pharmacists Association</td>
<td>International Nurses Society on Addictions</td>
</tr>
<tr>
<td>American College of Emergency Physicians</td>
<td>National Association for Community Health Centers</td>
</tr>
<tr>
<td>American Dental Association</td>
<td>National Association of Social Workers</td>
</tr>
<tr>
<td>American Medical Association</td>
<td>National Council for Behavioral Health</td>
</tr>
<tr>
<td>American Osteopathic Academy of Addiction Medicine</td>
<td>The National Judicial College</td>
</tr>
<tr>
<td>American Psychiatric Association</td>
<td>Physician Assistant Education Association</td>
</tr>
<tr>
<td>American Psychiatric Nurses Association</td>
<td>Society for Academic Emergency Medicine</td>
</tr>
</tbody>
</table>
Educate. Train. Mentor

@PCSSProjects

www.facebook.com/pcssprojects/

www.pcssNOW.org

pcss@aaap.org

Funding for this initiative was made possible (in part) by grant no. 1H79TI081968 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.